Rekah Pharmaceutical Industry Ltd.

TASE:REKA Voorraadrapport

Marktkapitalisatie: ₪162.3m

Rekah Pharmaceutical Industry Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Rekah Pharmaceutical Industry heeft een totaal eigen vermogen van ₪169.2M en een totale schuld van ₪94.0M, wat de schuld-eigenvermogensverhouding op 55.6% brengt. De totale activa en totale passiva bedragen respectievelijk ₪451.8M en ₪282.7M. De EBIT Rekah Pharmaceutical Industry is ₪18.1M waardoor de rentedekking 2.7 is. Het heeft contanten en kortetermijnbeleggingen van ₪5.4M.

Belangrijke informatie

55.6%

Verhouding schuld/eigen vermogen

₪93.97m

Schuld

Rente dekkingsratio2.7x
Contant₪5.45m
Aandelen₪169.15m
Totaal verplichtingen₪282.68m
Totaal activa₪451.83m

Recente financiële gezondheidsupdates

Recent updates

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₪225.0M ) REKA } overtreffen de korte termijn passiva ( ₪151.0M ).

Langlopende schulden: De kortetermijnactiva REKA ( ₪225.0M ) overtreffen de langetermijnschulden ( ₪131.7M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 52.3% ) REKA wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van REKA is de afgelopen 5 jaar gedaald van 58.6% naar 55.6%.

Schuldendekking: De schuld van REKA wordt goed gedekt door de operationele kasstroom ( 25.7% ).

Rentedekking: De rentebetalingen van REKA op haar schulden worden niet goed gedekt door EBIT ( 2.7 x dekking).


Balans


Ontdek gezonde bedrijven